Document is current
Any future updates will be listed below
-
Authors
Beffinger, Michal https://orcid.org/0000-0002-6916-7517
Schellhammer, Linda https://orcid.org/0000-0001-6044-033X
Taskoparan, Betül https://orcid.org/0000-0003-1890-1547
Deplazes, Sereina https://orcid.org/0009-0007-0064-3160
Salazar, Ulisse https://orcid.org/0009-0008-8041-3222
Tatari, Nazanin https://orcid.org/0000-0002-0003-6121
Seehusen, Frauke
von Balthazar, Leopold
Zinner, Carl Philipp https://orcid.org/0000-0003-1609-0920
Spath, Sabine https://orcid.org/0000-0002-2689-1951
Shekarian, Tala
Ritz, Marie-Françoise https://orcid.org/0000-0002-5650-9987
McDaid, Marta
Egloff, Pascal
Zimmermann, Iwan https://orcid.org/0000-0003-3476-4749
Okada, Hideho https://orcid.org/0000-0003-0076-9920
Ward, E. Sally
Rohrer, Jack
Seeger, Markus A. https://orcid.org/0000-0003-1761-8571
Buch, Thorsten https://orcid.org/0000-0002-2236-9074
Hutter, Gregor https://orcid.org/0000-0002-7570-3902
vom Berg, Johannes https://orcid.org/0000-0002-4086-1564
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 9 May 2025
First Online: 22 May 2025
Competing interests
: The here described compartment-locked IL-12Fc is covered by patent applications WO2020201167A1, WO2020201168A1, and EP24195766 of the University of Zurich, licensed to InCephalo AG. This results in a conflict of interest for coauthors L.S., B.T., M.B., S.D., S.S., T.B., and J.v.B. as co-inventors and/or employees of InCephalo AG. T.B., G.H., M.B., and J.v.B. have equity interests in InCephalo AG. J.v.B. has received speaker fees from Bristol-Myer Squibb. M.A.S. and I.Z. are shareholders of Linkster Therapeutics AG. U.S. has received employee options in Anaveon AG. E.S.W. is an inventor or co-inventor on patents describing antibody repertoire technology (owned by Medical Research Council, UK), half-life extension technology, Abdeg technology, targeting the HER2/HER3 axis, and detection of phosphatidylserine-positive exosomes (owned by UT Southwestern Medical Center or jointly by UT Southwestern Medical Center and argenx BV). E.S.W. is a co-inventor on pending or issued patents describing engineered antibody-drug conjugates and selective depletion of antibodies (jointly owned by UT Southwestern Medical Center and Texas A&M University). E.S.W. has a financial interest in Argenx BV. The remaining authors declare no competing interests.
